Examining gut bacteria and blood metabolites in pancreatic cancer and chronic pancreatitis patients
Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis
This study is trying to see if the bacteria in the gut and certain blood markers can help us understand pancreatic cancer and chronic pancreatitis by comparing samples from patients and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06411470 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect throat swabs, saliva, feces, and serum samples from patients diagnosed with pancreatic cancer, chronic pancreatitis, and healthy individuals. The goal is to analyze and clarify the characteristics of oral flora and serum metabolome specifically in pancreatic cancer patients. By comparing these samples across different groups, the study seeks to identify potential biomarkers or patterns associated with pancreatic cancer and chronic pancreatitis. This approach may provide insights into the role of gut microbiota and metabolites in these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals with a confirmed diagnosis of pancreatic ductal adenocarcinoma or chronic pancreatitis, as well as healthy individuals for comparison.
Not a fit: Patients who are pregnant, have coagulation disorders, or have used antibiotics or probiotics in the past three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers for early detection and monitoring of pancreatic cancer and chronic pancreatitis.
How similar studies have performed: While the specific approach of this study may be novel, similar studies examining the gut microbiome and metabolomics in cancer have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1.Pathologic diagnosis of pancreatic ductal adenocarcinoma；Diagnosis of CP defined as having obvious morphological features of CP (i.e., the presence of pancreatic calcifications on CT scan and/or magnetic resonance cholangiopancreatography)；Other benign disease populations without pancreatic lesions. Exclusion Criteria: 1. Pregnant women. 2. Patients with coagulation disorders who are unable to undergo blood tests. 3. Have a history of using antibiotics or probiotics within the past 3 months.
Where this trial is running
Shanghai, Shanghai Municipality
- Changhai Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiangyu Kong, MD
- Email: xiangyukong185@hotmail.com
- Phone: 13564644397
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.